Asahi Kasei Pharma obtains approval to manufacture and sell Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg in Japan

On 23 Dec 2022, Asahi Kasei Pharma obtained approval to manufacture and sell Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg (generic name: isavuconazonium sulfate, development code: AK1820) in Japan for treatment of the fungal infections of aspergillosis, mucormycosis, and cryptococcosis. Isavuconazonium sulfate was created as a new antifungal agent by Basilea Pharmaceutica International Ltd, Allschwil (Basilea) of Switzerland. Asahi Kasei Pharma obtained exclusive rights to develop and commercialize isavuconazonium sulfate in Japan in Sep 2016, and after advancing its development, applied for approval to manufacture and sell it in Japan in Sep 2021. Original source: Asahi Kasei Corp, website: http://www.asahi-kasei.co.jp/asahi/en/, Copyright Asahi Kasei Corporation 2022.
patents and technical know-how; regulations and rulings; antifungal drugs; Cresemba; isavuconazonium sulfate; Asahi Kasei Pharma; Basilea Pharmaceutica [...]